Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (121-130 of 158) with videos related to

Pageof 16
Sort By:
Vaccines|May 7, 2025
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 StudiesAnna Sicuranza, Massimo Breccia, Francesco Iuliano, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.
Leukemia & Lymphoma|November 6, 2020
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemiaFabio Efficace, Alessandra Iurlo, Andrea Patriarca, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Journal of Clinical Medicine|November 20, 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani, Giovanna Rege Cambrin, Paola Berchialla, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Pageof 16

Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Vaccines|May 7, 2025
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 StudiesAnna Sicuranza, Massimo Breccia, Francesco Iuliano, et al.
American Journal of Hematology|May 4, 2017
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinibFausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, et al.
Leukemia|July 1, 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemiaMarkus Pfirrmann, Richard E Clark, Witold Prejzner, et al.
Leukemia & Lymphoma|November 6, 2020
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemiaFabio Efficace, Alessandra Iurlo, Andrea Patriarca, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Journal of Clinical Medicine|November 20, 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani, Giovanna Rege Cambrin, Paola Berchialla, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.
Pageof 16